Updates are available Correction dated 2021-09-29
Click to view Correction: https://doi.org/10.1038/s41557-021-00823-x
-
Authors
Abbasov, Mikail E.
Kavanagh, Madeline E. https://orcid.org/0000-0002-4735-1559
Ichu, Taka-Aki
Lazear, Michael R. https://orcid.org/0000-0001-5313-4262
Tao, Yongfeng
Crowley, Vincent M.
am Ende, Christopher W.
Hacker, Stephan M. https://orcid.org/0000-0001-5420-4824
Ho, Jordan
Dix, Melissa M.
Suciu, Radu
Hayward, Matthew M.
Kiessling, Laura L.
Cravatt, Benjamin F. https://orcid.org/0000-0001-5330-3492
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA231991)
- License Information
-
More Information
Article History
Received: 17 September 2020
Accepted: 5 July 2021
First Online: 9 September 2021
Change Date: 29 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41557-021-00823-x
Competing interests
: B.F.C. is a founder and scientific advisor to Vividion Therapeutics, a biotechnology company interested in developing small-molecule therapeutics.
